Figure 1.

Schematic of the study flow [1]. We mined miRNA candidates from next generation sequencing experiments from the literature [2]. We designed a custom microarray using these candidates [11,877] and hybridized different tissues and blood to assess which candidates are more likely real miRNAs [3]. From the identified high confidence miRNAs [2,267], we built a second custom microarray, which was used in the current study to measure the differential expression in patients with different diseases and controls [4]. We performed statistical evaluation and added the results to our miRNA repositories and analysis pipelines [5]. We selected several candidate precursors to perform validation with Northern blotting. PD = Parkinson’s disease; NSCLC = non-small cell lung cancer; SCLC = small cell lung cancer; NTLD = non-tumor lung disease.